Zambia Pharmaceuticals and Healthcare Report Q2 2012


February 28, 2012
38 Pages - SKU: BMI3800516
License type:
Countries covered: Zambia

BMI View: We believe Zambia is rapidly becoming one of the most promising markets in Sub-Saharan Africa. An increased focus on healthcare and preventing corruption has attracted donations and loans from the international community that, alongside a record healthcare budget, will help to revolutionise its provision of healthcare and its focus on human capital. Decentralising healthcare provision should expand access substantially. In the short term, this will not benefit multinational drugmakers a great deal as the majority of the rural population is very poor and generic drugs will continue to dominate prescription patterns. However, in the longer term, it will drive sales of drugs as the country continues to develop.

Headline Expenditure Projections Pharmaceuticals: ZMK950bn (US$196mn) in 2011 to ZMK1,128bn (US$231mn) in 2012; +18.7% in local currency terms and +18.2% in US dollar terms.

Healthcare: ZMK5,169bn (US$1.06bn) in 2011 to ZMK6,190bn (US$1.269bn) in 2012; +19.8% in local currency terms and +19.3% in US dollar terms.

Risk/Reward Rating: In Q212, Zambia remained steady at 21st best market in the MEA region in BMI’s proprietary Risk/Reward Ratings (RRR) matrix with a score of 39.6.

Key Trends & Developments

Zambia has released its proposed budget for 2012. In line with BMI’s view that the election of Sata could have upside risks for public healthcare spending, the incoming government has promised to increase the Ministry of Health’s budget by 45%, from ZMK1,772.9bn (US$367mn) in 2011 to ZMK2579.9bn (US$537mn) in 2012.

From the beginning of December 2011 to mid-January 2012, Zambia has managed to obtain US$200mn in aid and low-interest loans for social infrastructure and anti-poverty measures. Donors, investors and governments are becoming more willing to invest in the country now that doubt over the elections has passed and the government’s anticorruption measures have started to take effect.

The Zambian government announced in December 2011 that it plans to hire and train 2,500 staff and, more importantly, it is looking to raise remuneration for healthcare professionals to encourage members of the diaspora to return to the country and bring back their knowledge and skills.

BMI Economic View: The decision by the government of Zambia to repossess Zamtel from Libya’s LAP Green Network demonstrates newly installed President Michael Sata’s determination to fundamentally change the way the public sector does business. Although operational risk has increased under his presidency, we stress that the original transaction was decried by Sata (and others) in 2010, the question of reversing the sale has been in the works for many months, and, most importantly, we do not believe that there is a significant risk of nationalisation for other firms (such as copper miners) operating in Zambia.

BMI Political View: Despite some uncertainty regarding policy in Zambia following the presidential election of populist candidate Michael Sata, investment commitments into the country were robust throughout 2011. Investments have poured into the globally competitive mining sector, and there has been increased interest in manufacturing, construction and energy.



More Manufacturing, Packaging & Detailing reports by Business Monitor International

Nigeria Pharmaceuticals and Healthcare Report Q3 2013 by Business Monitor International
Executive SummaryBMI View: Boosting bilateral co-operation between Nigerian buyers and Indian drugmakers will directlyobstruct the Nigerian government's goal to increase self-sufficiency in medicines production. We ...
Namibia Pharmaceuticals and Healthcare Report Q3 2013 by Business Monitor International
BMI View: We expect Namibia's negative pharmaceutical trade balance to widen as demand for medicinescontinues to be met by imports, and poor local manufacturing sees ...
Mexico Pharmaceuticals and Healthcare Report Q3 2013 by Business Monitor International
BMI View: The improving performance of Mexico's regulatory system presents more opportunities formultinational pharmaceutical companies seeking to enter the Mexican pharmaceutical market. On the backof ...
Gabon Pharmaceuticals and Healthcare Report Q3 2013 by Business Monitor International
BMI View: Increased longevity in developed markets translates into an increased demand for care for theelderly, healthcare services and medicines. However, despite increased life expectancy, ...
See all reports like this >>

More Zambia Manufacturing, Packaging & Detailing reports

Zambia Pharmaceuticals and Healthcare Report Q2 2013 by Business Monitor International
BMI View: A politically stable and attractive sub-Saharan country for international investment thanks to its rich mineral reserves, Zambia's healthcare system is notable for its ...
Zambia Pharmaceuticals and Healthcare Report Q1 2013 by Business Monitor International
BMI View: The majority of investment in Zambia's healthcare market stems from international aidagencies - so the news that the government has increased its allocation ...
Zambia Pharmaceuticals and Healthcare Report Q3 2012 by Business Monitor International
BMI View: The fundamentals of Zambia’s healthcare industry growth story remain strong with macroeconomic growth, returning international donations and government spending on healthcare forecast to ...
See all reports like this >>

More Zambia reports

D&B Country RiskLine Report: Zambia by Dun & Bradstreet Inc.
This D&B Country RiskLine Report will help you analyze the risks, opportunities and likely payment delays when doing business in this country. It includes ...
See all reports like this >>

 
Research assistance
We can help you find what you need. Call us or write us:
US: 800.298.5699
Int'l: +1.240.747.3093
Need help in your search?
 
Join Alert Me now!
Receive bi-weekly email alerts on new market research

Sign up today!